Nanomed

About:

Nanomed is a provider of graphene biosensor products used in life science research, drug discovery, and diagnostics, and health-monitoring.

Website: http://www.nanomedical.com/

Twitter/X: NanomedSD

Top Investors: Serra Ventures, EvoNexus, Sand Hill Angels, Castile Ventures

Description:

Nanomed is a provider of graphene biosensor products used in life science research, drug discovery, and diagnostics, and health-monitoring. They provide fast and affordable tools for small molecule drug discovery. They have developed a breakthrough electrical assay based on proprietary Field Effect Biosensing (FEB) technology that detects molecular interactions. This technology employs a unique graphene biosensor to enable label-free, highly sensitive binding studies of small molecules to proteins. With a wide dynamic range, small sample requirements, and minimal signal contributions from common solvents and detergents, their technology complements existing technology and accelerates small molecule drug discovery. As the world’s leading mass-manufacturer of next-generation graphene biosensors, their mission is to transform the healthcare industry with innovative new products that accelerate cutting-edge life science and drug discovery research. It was founded in 2013 and is based in San Diego, California.

Total Funding Amount:

$2.4M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

San Diego, California, United States

Founded Date:

2013-01-01

Contact Email:

info(AT)nanomedical.com

Founders:

Brett Goldsmith, Ross Bundy

Number of Employees:

11-50

Last Funding Date:

2020-10-23

IPO Status:

Private

Industries:

© 2025 bioDAO.ai